An attenuated mutant of avian pathogenic Escherichia coli serovar O78: a possible live vaccine strain for prevention of avian colibacillosis.
Here construction of an attenuated mutant of an avian pathogenic Escherichia coli serovar O78 using an allelic exchange procedure is described. The mutant AESN1331, which carries a deletion in the crp gene, lost tryptophan deaminase activity and therefore lacked the ability to produce indole. The mutant strain additionally lacked the ability to adsorb Congo red, no longer fermented sugars other than glucose and L-arabinose, did not harbor four known virulence-associated genes (iss, tsh, cvaA, papC), and was susceptible to many antimicrobials, with the exception of nalidixic acid. The lethal dose (LD(50)  value) of the mutant strain on intravenous challenge in chickens was approximately 10-fold higher than that of the parent strain. Additionally, the mutant strain was rapidly eliminated from chickens, being detected in the respiratory tract only on the first day post-inoculation by fine spray. Administration of the mutant strain via various routes such as spray and eye drop for chickens, as well as in ovo inoculation for embryonated egg, evoked an effective immune response that protected against a virulent wild-type E. coli O78 strain. Specifically, after immunization with the mutant strain, chickens challenged intravenously with an E. coli O78 strain exhibited decreases in mortality, clinical scores, organ lesion scores, and recovery of the challenge strain from organs compared to non-immunized chickens. These findings suggest that AESN1331 is a suitable candidate for a live vaccine strain to protect chickens from colibacillosis caused by avian E. coli O78.
Nippon Institute for Biological Science, 9-2221-1 Shinmachi, Ome, Tokyo 198-0024, Japan.
Tetsuji
T
Nagano
Rie
R
Kitahara
Shinya
S
Nagai
D061605:Administration, Intravenous; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000942:Antigens, Bacterial / Q000276:immunology; D002642:Chick Embryo; D002645:Chickens / Q000276:immunology / Q000382:microbiology*; D003224:Congo Red; D002373:Cyclic AMP Receptor Protein / Q000235:genetics / Q000378:metabolism; D004926:Escherichia coli / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity*; D004927:Escherichia coli Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D029968:Escherichia coli Proteins / Q000235:genetics / Q000378:metabolism; D022361:Escherichia coli Vaccines / Q000276:immunology*; D017353:Gene Deletion; D005798:Genes, Bacterial; D007928:Lethal Dose 50; D008826:Microbial Sensitivity Tests; D009268:Nalidixic Acid / Q000494:pharmacology; D011201:Poultry Diseases / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology
D000900:Anti-Bacterial Agents; D000942:Antigens, Bacterial; D002373:Cyclic AMP Receptor Protein; D029968:Escherichia coli Proteins; D022361:Escherichia coli Vaccines; D014613:Vaccines, Attenuated; C481662:crp protein, E coli; D009268:Nalidixic Acid; D003224:Congo Red